Switzerland· 41217111
Holoxan
A ifosfamide product containing ifosfamidum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ifosfamide is registered in 15 of 19 countries.
Countries holding a registration under ATC L01AA06 (ifosfamide), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 9 of them publish a price we can compare per daily dose
Ifosfamide · ATC L01AA06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ifosfamide costs, country by country.
Normalised to the WHO defined daily dose (0.7 g), so markets compare like for like.
- Switzerland: $52.67 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Ifosfamide · price per daily dose (0.7 g)
USD · FX 28 Sept 2026
- CH Switzerland$52.67
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- ifosfamidum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01AA06
- ATC class
- Ifosfamide
- Defined daily dose
- 0.7 g, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680412171111Durchstf 1 StkCHF 101.9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
514 interactions on record for ifosfamide.
Graded by severity as the source publishes them — 41 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ifosfamide · interactions on record
514 records
- 41 severe
- 385 moderate
- 16 minor
- 72 info
Most severe, free to view
- Nalidixic acidJ01MB02severe
- CidofovirJ05AB12severe
- ThiotepaL01AC01severe
- CladribineL01BB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ifosfamide in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaHOLOXANBaxter Oncology GmbH, Halle
- United StatesIFEXBaxter Healthcare Corporation
- United KingdomIfosfamide 1g powder for concentrate for solution for injection vialsBaxter Healthcare Ltd
- FinlandHoloxanOrifarm Oy
- BelgiumHoloxan 1 gBaxter
- NorwayHoloxanBaxter Medical AB
- GermanyHoloxanBaxter Deutschland Gmbh
- SwedenHoloxan 1000 mg Pulver till injektions-/infusionsvätska, lösningBaxter Medical AB
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Holoxan
- Belgium · Holoxan
- Bulgaria · Холоксан
- Czechia · Holoxan
- Germany · Holoxan, Ifo-Cell
- Denmark · Holoxan
- Estonia · Holoxan
- Spain · Tronoxal
- Finland · Holoxan
- France · Holoxan, Ifosfamide Eg
- United Kingdom (Northern Ireland) · Ifosfamide Baxter Healthcare
- Greece · Holoxan
- Croatia · Holoxan
- Hungary · Holoxan
- Ireland · Mitoxana
- Iceland · Holoxan
- Italy · Holoxan
- Lithuania · Holoxan
- Luxembourg · Holoxan
- Latvia · Holoxan
- Malta · Mitoxana
- Netherlands · Holoxan
- Norway · Holoxan
- Poland · Holoxan
- Portugal · Holoxan
- Romania · Holoxan
- Sweden · Holoxan
- Slovenia · Holoxan
- Slovakia · Holoxan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dfcb5493-4fcf-49c1-bdf8-20c7233c9d64 GET /v1/drugs/dfcb5493-4fcf-49c1-bdf8-20c7233c9d64?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ifosfamidum 2000 mg",
"valid_from": "1982-03-15",
"limitations": null,
"galenic_form": "Trockensub 2 g",
"therapeutic_area": null,
"sl_inclusion_date": "1982-03-15",
"self_retention_pct": 10
}See everything about ifosfamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.